In today’s briefing:
- BSEM: Growth Continue to Accelerate
- Nanocarrier (4571 JP): Q1 FY03/25 flash update
- SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
- SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
- VIRI: Enrollment Complete in Phase 2a Long COVID Trial Results Expected in October 2024
- XFOR: First Commercial Sales of XOLREMDI
BSEM: Growth Continue to Accelerate
- BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
- The company released its 2Q2024 results that blew past estimates as demand for its innovative wound care products accelerates.
- The company also outlined plans to continue and advance the rapid growth seen in 2024.
Nanocarrier (4571 JP): Q1 FY03/25 flash update
- The company reported no sales in Q2 FY03/23, with operating and recurring losses narrowing YoY due to decreased SG&A expenses.
- The company shifted its focus to mRNA drug candidates and IP licensing, enhancing collaborations and research progress.
- The company ended its fertility treatment support business in May 2024 and ceased sales of Depth products in December 2022.
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
- On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update.
- The company is on track to initiate the confirmatory Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of patients with early stage cutaneous T cell lymphoma (CTCL) in the second half of 2024.
- In support of this, the company recently announced positive clinical results from a comparability study between HyBryte and Valchlor , which showed a three-fold higher response rate over a 12-week treatment period and a more favorable safety profile for HyBryte.
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
- On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update.
- The company is on track to initiate the confirmatory Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of patients with early stage cutaneous T cell lymphoma (CTCL) in the second half of 2025.
- In support of this, the company recently announced positive clinical results from a comparability study between HyBryte and Valchlor , which showed a three-fold higher response rate over a 12-week treatment period and a more favorable safety profile for HyBryte.
VIRI: Enrollment Complete in Phase 2a Long COVID Trial Results Expected in October 2024
- On August 8, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the second quarter of 2024 and provided a business update.
- The company recently announced that the Phase 2a clinical trial of IMC-2 (valacycovir+celecoxib) has completed enrollment and we anticipate topline results from the trial in October 2024.
- Ongoing blinded safety analysis of the Phase 2a study indicates that study drug has been well tolerated with no serious adverse events reported.
XFOR: First Commercial Sales of XOLREMDI
- On August 8, 2024, X4 Pharmaceuticals, Inc. (XFOR) announced financial results for the second quarter of 2024 and provided a business update.
- Following the commercial launch of XOLREMDI (mavorixafor) in April 2024 the company recorded the first commercial sales of the drug, which totaled approximately $0.6 million in the second quarter of 2024.
- We anticipate the full data set from the Phase 2 trial of mavorixafor in chronic neutropenia (CN) to be presented in November 2024.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
